Company: ZVRA
Filing Date: 2025-04-16
Form Type: PRRN14A
Source: 0000897069-25-000815
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-16
Form: PRRN14A
Chunk 1
---
 Suite 103, Celebration, FL 34747, in connection with our solicitation of proxies for use at the 2025 Annual Meeting of Stockholders of the Company scheduled to be held on [●], 2025, at [●] Eastern Time, which will be held virtually on the internet at http://www.cesonlineservices.com/zvra25_vm and at any and all adjournments, continuations or postponements thereof (the “ Annual Meeting”). According to the Company’s proxy statement, the record date for the Annual Meeting is [●], 2025. Only stockholders of record at the close of business on that date may vote at the Annual Meeting or any continuation, adjournment or postponement thereof. This solicitation is being conducted by Mr. Daniel J. Mangless (the “ Proponent”), together with the other participants named herein (collectively, the “ Participants”). As of the date hereof, the Proponent beneficially owns an aggregate of 100 shares of Common Stock in record name and 1,521,095 shares of Common Stock in street name, representing approximately 2.8% of the shares of Common Stock, as reported to be outstanding by the Company as of March 7, 2025. As more fully discussed in this Proxy Statement, the proxies are being solicited to be used at the Annual Meeting for the following purpose: 1. To elect Mr. Travis C. Mickle, PhD and Mr. Arthur C. Regan (each of Messrs. Mickle and Regan, a “ Nominee”, and collectively, the “ Nominees”) as directors of Zevra (the “ Board of Directors” or the “ Board”). This Proxy Statement is first being sent or given to stockholders on or about [●], 2025. THIS SOLICITATION IS BEING MADE BY DANIEL J. MANGLESS, AND NOT ON
BEHALF OF THE BOARD OF DIRECTORS OF THE COMPANY. While the election at Zevra’s 2023 Annual Meeting of Stockholders brought about important change, including new leadership with extensive commercial experience, I believe that other important governance issues remain unresolved, to the detriment of all Zevra stockholders. Namely, I believe these unresolved issues include the Company’s governance practice of having a classified board and the use of a plurality voting standard for the election of directors in uncontested elections. I believe declassification would provide stockholders the ability to evaluate each director annually, which is